{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:33:12Z","timestamp":1791329592032,"version":"4.3.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40744-022-00519-9","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T12:02:43Z","timestamp":1677844963000},"page":"707-727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis"],"prefix":"10.1007","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02504268","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8482","authenticated-orcid":false,"given":"Paul","family":"Emery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian P.","family":"Bykerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W. J.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Citera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"3rd","given":"Clifton O.","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashis","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Soule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Nys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean E.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karissa L.","family":"Lozenski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Hsiang Gary","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"519_CR1","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00296-016-3506-3","volume":"36","author":"E Martin-Mola","year":"2016","unstructured":"Martin-Mola E, Balsa A, Garcia-Vicuna R, et\u00a0al. Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. Rheumatol Int. 2016;36:1043\u201363.","journal-title":"Rheumatol Int"},{"key":"519_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ, et\u00a0al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685\u201399.","journal-title":"Ann Rheum Dis"},{"key":"519_CR3","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et\u00a0al. 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73:1108\u201323.","journal-title":"Arthritis Rheumatol"},{"key":"519_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, et\u00a0al. American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70:404\u201313.","journal-title":"Ann Rheum Dis"},{"key":"519_CR5","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s10067-017-3588-7","volume":"36","author":"LR Harrold","year":"2017","unstructured":"Harrold LR, Litman HJ, Connolly SE, et\u00a0al. A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity\/remission in clinical practice? Clin Rheumatol. 2017;36:1215\u201320.","journal-title":"Clin Rheumatol"},{"key":"519_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1136\/annrheumdis-2014-206993","volume":"74","author":"K Raza","year":"2015","unstructured":"Raza K, Filer A. The therapeutic window of opportunity in rheumatoid arthritis: does it ever close? Ann Rheum Dis. 2015;74:793\u20134.","journal-title":"Ann Rheum Dis"},{"key":"519_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135327","volume":"10","author":"C Barnabe","year":"2015","unstructured":"Barnabe C, Sun Y, Boire G, et\u00a0al. Heterogeneous disease trajectories explain variable radiographic, function and quality of life outcomes in the Canadian early arthritis cohort (CATCH). PLoS\u00a0One. 2015;10: e0135327.","journal-title":"PLoS\u00a0One"},{"key":"519_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/1759720X17720366","volume":"9","author":"S Ajeganova","year":"2017","unstructured":"Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther Adv Musculoskelet Dis. 2017;9:249\u201362.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"519_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13075-015-0912-y","volume":"18","author":"L Heimans","year":"2016","unstructured":"Heimans L, Akdemir G, Boer KV, et\u00a0al. Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study). Arthritis Res Ther. 2016;18:23.","journal-title":"Arthritis Res Ther"},{"key":"519_CR10","doi-asserted-by":"publisher","first-page":"ii15","DOI":"10.1093\/rheumatology\/kew352","volume":"55","author":"Y Tanaka","year":"2016","unstructured":"Tanaka Y. Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis. Rheumatology (Oxford). 2016;55:ii15\u201322.","journal-title":"Rheumatology (Oxford)"},{"key":"519_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nri.2016.124","volume":"17","author":"V Malmstrom","year":"2017","unstructured":"Malmstrom V, Catrina AI, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol. 2017;17:60\u201375.","journal-title":"Nat Rev Immunol"},{"key":"519_CR12","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker JC, Schiff M, et\u00a0al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114\u201323.","journal-title":"N Engl J Med"},{"key":"519_CR13","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1002\/art.30463","volume":"63","author":"MC Genovese","year":"2011","unstructured":"Genovese MC, Covarrubias A, Leon G, et\u00a0al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheumatol. 2011;63:2854\u201364.","journal-title":"Arthritis Rheumatol"},{"key":"519_CR14","first-page":"983","volume":"74","author":"J Sokolove","year":"2015","unstructured":"Sokolove J, Schiff M, Fleischmann R, et\u00a0al. Impact of baseline anti-cyclic citrullinated peptide 2 antibody titre on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis. 2015;74:983\u20134.","journal-title":"Ann Rheum Dis"},{"key":"519_CR15","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et\u00a0al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569\u201381.","journal-title":"Arthritis Rheum"},{"key":"519_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1136\/ard.60.4.344","volume":"60","author":"MC Greenwood","year":"2001","unstructured":"Greenwood MC, Doyle DV, Ensor M. Does the Stanford Health Assessment Questionnaire have potential as a monitoring tool for subjects with rheumatoid arthritis? Ann Rheum Dis. 2001;60:344\u20138.","journal-title":"Ann Rheum Dis"},{"key":"519_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","volume":"73","author":"M Schiff","year":"2014","unstructured":"Schiff M, Weinblatt ME, Valente R, et\u00a0al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73:86\u201394.","journal-title":"Ann Rheum Dis"},{"key":"519_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/art.30158","volume":"63","author":"JM Kremer","year":"2011","unstructured":"Kremer JM, Blanco R, Brzosko M, et\u00a0al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63:609\u201321.","journal-title":"Arthritis Rheum"},{"key":"519_CR19","first-page":"557","volume":"20","author":"GA Wells","year":"1993","unstructured":"Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient\u2019s perspective. J Rheumatol. 1993;20:557\u201360.","journal-title":"J Rheumatol"},{"key":"519_CR20","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R van Vollenhoven","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, et\u00a0al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatol. 2020;72:1607\u201320.","journal-title":"Arthritis Rheumatol"},{"key":"519_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg JE, et\u00a0al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322:315\u201325.","journal-title":"JAMA"},{"key":"519_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10067-013-2468-z","volume":"33","author":"C Sheehy","year":"2014","unstructured":"Sheehy C, Evans V, Hasthorpe H, Mukhtyar C. Revising DAS28 scores for remission in rheumatoid arthritis. Clin Rheumatol. 2014;33:269\u201372.","journal-title":"Clin Rheumatol"},{"key":"519_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Burmester GR, Bykerk VP, et\u00a0al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74:19\u201326.","journal-title":"Ann Rheum Dis"},{"key":"519_CR24","first-page":"3758","volume":"9","author":"D Liu","year":"2017","unstructured":"Liu D, Yuan N, Yu G, Song G, Chen Y. Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission? Am J Transl Res. 2017;9:3758\u201375.","journal-title":"Am J Transl Res"},{"key":"519_CR25","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1136\/annrheumdis-2013-204632","volume":"74","author":"JS Smolen","year":"2015","unstructured":"Smolen JS, Emery P, Ferraccioli GF, et\u00a0al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis. 2015;74:843\u201350.","journal-title":"Ann Rheum Dis"},{"key":"519_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000840","volume":"5","author":"P Emery","year":"2019","unstructured":"Emery P, Burmester GR, Bykerk VP, et\u00a0al. Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study. RMD Open. 2019;5: e000840.","journal-title":"RMD Open"},{"key":"519_CR27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/annrheumdis-2018-213271","volume":"78","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi T, Genovese MC, Haraoui B, et\u00a0al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis. 2019;78:171\u20138.","journal-title":"Ann Rheum Dis"},{"key":"519_CR28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13075-019-1937-4","volume":"21","author":"Y Tanaka","year":"2019","unstructured":"Tanaka Y, Smolen JS, Jones H, Szumski A, Marshall L, Emery P. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. Arthritis Res Ther. 2019;21:164.","journal-title":"Arthritis Res Ther"},{"key":"519_CR29","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1136\/annrheumdis-2016-209201","volume":"75","author":"G Schett","year":"2016","unstructured":"Schett G, Emery P, Tanaka Y, et\u00a0al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016;75:1428\u201337.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"519_CR30","doi-asserted-by":"publisher","first-page":"ii124","DOI":"10.1136\/annrheumdis-2012-202350","volume":"72","author":"Y Tanaka","year":"2013","unstructured":"Tanaka Y. Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal? Ann Rheum Dis. 2013;72(Suppl 2):ii124\u20137.","journal-title":"Ann Rheum Dis"},{"key":"519_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13075-017-1484-9","volume":"20","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Szumski A, Koenig AS, Jones TV, Marshall L. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. Arthritis Res Ther. 2018;20:8.","journal-title":"Arthritis Res Ther"},{"key":"519_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000222","volume":"2","author":"W Zhang","year":"2016","unstructured":"Zhang W, Bansback N, Sun H, Pedersen R, Kotak S, Anis AH. Impact of etanercept tapering on work productivity in patients with early rheumatoid arthritis: results from the PRIZE study. RMD Open. 2016;2: e000222.","journal-title":"RMD Open"},{"key":"519_CR33","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1316133","volume":"371","author":"P Emery","year":"2014","unstructured":"Emery P, Hammoudeh M, FitzGerald O, et\u00a0al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med. 2014;371:1781\u201392.","journal-title":"N Engl J Med"},{"key":"519_CR34","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1136\/ard.2008.101121","volume":"68","author":"R Westhovens","year":"2009","unstructured":"Westhovens R, Robles M, Ximenes AC, et\u00a0al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68:1870\u20137.","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00519-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-022-00519-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00519-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T14:09:05Z","timestamp":1682604545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-022-00519-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["519"],"URL":"https:\/\/doi.org\/10.1007\/s40744-022-00519-9","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"assertion":[{"value":"8 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}